These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38371953)

  • 1. ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks.
    Alfaleh MA; Alsulaiman RM; Almahboub SA; Nezamuldeen L; Zawawi A; Aljehani ND; Yasir M; Abdulal RH; Alkhaldi R; Helal A; Alamri SS; Malki J; Alhabbab RY; Abujamel TS; Alhakamy NA; Alnami A; Algaissi A; Hassanain M; Hashem AM
    Antib Ther; 2024 Jan; 7(1):53-66. PubMed ID: 38371953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
    Joseph J; Karthika T; Das VRA; Raj VS
    Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.
    Zhao G; Du L; Ma C; Li Y; Li L; Poon VK; Wang L; Yu F; Zheng BJ; Jiang S; Zhou Y
    Virol J; 2013 Aug; 10():266. PubMed ID: 23978242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for
    Dick JK; Hicks D; Krishna VD; Sangala JA; Zandstra BT; Baehr C; Verbeek JS; Cragg MS; Cheeran MC; Pravetoni M; Hart GT
    bioRxiv; 2024 Jun; ():. PubMed ID: 38948747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses.
    Lim HT; Kok BH; Lim CP; Abdul Majeed AB; Leow CY; Leow CH
    Biomed Eng Adv; 2022 Dec; 4():100054. PubMed ID: 36158162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering ACE2 decoy receptors to combat viral escapability.
    Arimori T; Ikemura N; Okamoto T; Takagi J; Standley DM; Hoshino A
    Trends Pharmacol Sci; 2022 Oct; 43(10):838-851. PubMed ID: 35902282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection.
    Lu M; Yao W; Li Y; Ma D; Zhang Z; Wang H; Tang X; Wang Y; Li C; Cheng D; Lin H; Yin Y; Zhao J; Zhong G
    Microbiol Spectr; 2023 Aug; 11(4):e0110023. PubMed ID: 37395664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike.
    Trigueiro-Louro J; Correia V; Figueiredo-Nunes I; Gíria M; Rebelo-de-Andrade H
    Comput Struct Biotechnol J; 2020; 18():2117-2131. PubMed ID: 32913581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Close relatives of MERS-CoV in bats use ACE2 as their functional receptors.
    Xiong Q; Cao L; Ma C; Tortorici MA; Liu C; Si J; Liu P; Gu M; Walls AC; Wang C; Shi L; Tong F; Huang M; Li J; Zhao C; Shen C; Chen Y; Zhao H; Lan K; Corti D; Veesler D; Wang X; Yan H
    Nature; 2022 Dec; 612(7941):748-757. PubMed ID: 36477529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
    Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
    J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
    Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
    PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors.
    Alfaleh MA; Zawawi A; Al-Amri SS; Hashem AM
    MAbs; 2022; 14(1):2057832. PubMed ID: 35380919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models.
    Urano E; Itoh Y; Suzuki T; Sasaki T; Kishikawa JI; Akamatsu K; Higuchi Y; Sakai Y; Okamura T; Mitoma S; Sugihara F; Takada A; Kimura M; Nakao S; Hirose M; Sasaki T; Koketsu R; Tsuji S; Yanagida S; Shioda T; Hara E; Matoba S; Matsuura Y; Kanda Y; Arase H; Okada M; Takagi J; Kato T; Hoshino A; Yasutomi Y; Saito A; Okamoto T
    Sci Transl Med; 2023 Aug; 15(711):eadi2623. PubMed ID: 37647387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Plant-Produced Recombinant ACE2-Fc Fusion Protein as a Potential Therapeutic Agent Against SARS-CoV-2.
    Siriwattananon K; Manopwisedjaroen S; Kanjanasirirat P; Budi Purwono P; Rattanapisit K; Shanmugaraj B; Smith DR; Borwornpinyo S; Thitithanyanont A; Phoolcharoen W
    Front Plant Sci; 2020; 11():604663. PubMed ID: 33584747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses.
    Peng Y; Liu Y; Hu Y; Chang F; Wu Q; Yang J; Chen J; Teng S; Zhang J; He R; Wei Y; Bostina M; Luo T; Liu W; Qu X; Li YP
    Front Immunol; 2022; 13():1056272. PubMed ID: 36618428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
    Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
    J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a recombinant vaccine containing a spike S1-Fc fusion protein induced protection against MERS-CoV in human DPP4 knockin transgenic mice.
    Jung BK; An Y; Park JE; Chang KS; Jang H
    J Virol Methods; 2022 Jan; 299():114347. PubMed ID: 34728273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.